

Financial Tear Sheet

Primary IR Contact

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com
(mailto:invest@ctibiopharma.com)

Transfer Agent

Computershare

Mail:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078

Overnight Delivery:
Computershare Investor Services
250 Royall Street
Canton, MA 02021
United States of America

T: 312-588-4187
F: 312-601-4332
www.Computershare.com
(http://www.computershare.com)

Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$3.41**

Change
(%) ▼ 0.12 (3.40%)

Volume 94,034

52 Week Low \$2.70

Market Cap \$100,213,827

Rolling EPS -2.53

PE Ratio 0

Shares Outstanding 28,389,186

Data as of 07/21/17 12:17 p.m. ET



Recent Headlines & Events

Jul 13, 2017 - 4:05 p.m.

CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia

(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2286395)

Jun 15, 2017 - 1:31 a.m.

CTI BioPharma Receives \$10 Million Milestone Payment for TRISENOX®

(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2281044)

Jun 06, 2017 - 9:07 a.m.

CTI BioPharma Prices Underwritten Public Offering of \$45 Million of Convertible Preferred Stock

(phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2279193)

There are currently no events scheduled.

Ownership Summary

Shareholders

	 Holders 	 Value (\$MM) 	 % O/S 	 Shares
Institution	77	78.27	77.0	21,853,259
Mutual Fund	21	3.35	3.4	971,794
Insider *	11	24.27	17.5	4,969,236

**Insider values reflect direct beneficial ownership.*

Top Holders

	 Shares Held 	 % O/S 	 Share Change 	 Filing Date
BVF Partners L.P.	8,596,357	30.3	4,116,666	06/09/17
OrbiMed Advisors, LLC	5,000,000	17.6	5,000,000	06/09/17
Stonepine Capital Management, LLC	2,307,446	8.1	2,307,446	06/06/17
Baxalta, Inc.	1,567,398	5.5	0	01/01/17
NB Public Equity Komplementar ApS	1,356,635	4.8	90,000	12/31/16
The Vanguard Group, Inc.	812,498	2.9	53,343	03/31/17
BlackRock Institutional Trust Company, N.A.	352,059	1.2	842	03/31/17
Bianco (James A)	178,013	0.6	-153,379	02/10/17
Millennium Management LLC	159,120	0.6	114,070	03/31/17
Renaissance Technologies LLC	119,345	0.4	-54,704	03/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed.